Your browser doesn't support javascript.
loading
Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis.
Li, Zheqi; Wu, Yang; Yates, Megan E; Tasdemir, Nilgun; Bahreini, Amir; Chen, Jian; Levine, Kevin M; Priedigkeit, Nolan M; Nasrazadani, Azadeh; Ali, Simak; Buluwela, Laki; Arnesen, Spencer; Gertz, Jason; Richer, Jennifer K; Troness, Benjamin; El-Ashry, Dorraya; Zhang, Qiang; Gerratana, Lorenzo; Zhang, Youbin; Cristofanilli, Massimo; Montanez, Maritza A; Sundd, Prithu; Wallace, Callen T; Watkins, Simon C; Fumagalli, Caterina; Guerini-Rocco, Elena; Zhu, Li; Tseng, George C; Wagle, Nikhil; Carroll, Jason S; Jank, Paul; Denkert, Carsten; Karsten, Maria M; Blohmer, Jens-Uwe; Park, Ben H; Lucas, Peter C; Atkinson, Jennifer M; Lee, Adrian V; Oesterreich, Steffi.
Afiliação
  • Li Z; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Wu Y; Women's Cancer Research Center, Magee-Womens Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
  • Yates ME; Women's Cancer Research Center, Magee-Womens Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
  • Tasdemir N; School of Medicine, Tsinghua University, Beijing, P.R. China.
  • Bahreini A; Women's Cancer Research Center, Magee-Womens Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
  • Chen J; Integrative Systems Biology Program, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Levine KM; Medical Scientist Training Program, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
  • Priedigkeit NM; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Nasrazadani A; Women's Cancer Research Center, Magee-Womens Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
  • Ali S; Women's Cancer Research Center, Magee-Womens Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
  • Buluwela L; Department of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Arnesen S; Women's Cancer Research Center, Magee-Womens Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
  • Gertz J; Women's Cancer Research Center, Magee-Womens Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
  • Richer JK; Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Troness B; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • El-Ashry D; Women's Cancer Research Center, Magee-Womens Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
  • Zhang Q; Women's Cancer Research Center, Magee-Womens Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
  • Gerratana L; Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
  • Zhang Y; Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
  • Cristofanilli M; Department of Oncological Sciences, University of Utah, Salt Lake City, Utah.
  • Montanez MA; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
  • Sundd P; Department of Oncological Sciences, University of Utah, Salt Lake City, Utah.
  • Wallace CT; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
  • Watkins SC; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Fumagalli C; University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota.
  • Guerini-Rocco E; University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota.
  • Zhu L; Robert H. Lurie Cancer Center of Northwestern University, Feinberg School of Medicine, Chicago, Illinois.
  • Tseng GC; Robert H. Lurie Cancer Center of Northwestern University, Feinberg School of Medicine, Chicago, Illinois.
  • Wagle N; Department of Medicine (DAME) University of Udine, Udine, Italy.
  • Carroll JS; Robert H. Lurie Cancer Center of Northwestern University, Feinberg School of Medicine, Chicago, Illinois.
  • Jank P; Robert H. Lurie Cancer Center of Northwestern University, Feinberg School of Medicine, Chicago, Illinois.
  • Denkert C; Pittsburgh Heart, Lung and Blood Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
  • Karsten MM; Pittsburgh Heart, Lung and Blood Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
  • Blohmer JU; Center for Biological Imaging, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Park BH; Center for Biological Imaging, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Lucas PC; Division of Pathology and Laboratory Medicine, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
  • Atkinson JM; Division of Pathology and Laboratory Medicine, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
  • Lee AV; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Oesterreich S; Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania.
Cancer Res ; 82(7): 1321-1339, 2022 04 01.
Article em En | MEDLINE | ID: mdl-35078818
ABSTRACT
Constitutively active estrogen receptor α (ER/ESR1) mutations have been identified in approximately one-third of ER+ metastatic breast cancers. Although these mutations are known as mediators of endocrine resistance, their potential role in promoting metastatic disease has not yet been mechanistically addressed. In this study, we show the presence of ESR1 mutations exclusively in distant but not local recurrences in five independent breast cancer cohorts. In concordance with transcriptomic profiling of ESR1-mutant tumors, genome-edited ESR1 Y537S and D538G-mutant cell models exhibited a reprogrammed cell adhesive gene network via alterations in desmosome/gap junction genes and the TIMP3/MMP axis, which functionally conferred enhanced cell-cell contacts while decreasing cell-extracellular matrix adhesion. In vivo studies showed ESR1-mutant cells were associated with larger multicellular circulating tumor cell (CTC) clusters with increased compactness compared with ESR1 wild-type CTCs. These preclinical findings translated to clinical observations, where CTC clusters were enriched in patients with ESR1-mutated metastatic breast cancer. Conversely, context-dependent migratory phenotypes revealed cotargeting of Wnt and ER as a vulnerability in a D538G cell model. Mechanistically, mutant ESR1 exhibited noncanonical regulation of several metastatic pathways, including secondary transcriptional regulation and de novo FOXA1-driven chromatin remodeling. Collectively, these data provide evidence for ESR1 mutation-modulated metastasis and suggest future therapeutic strategies for targeting ESR1-mutant breast cancer.

SIGNIFICANCE:

Context- and allele-dependent transcriptome and cistrome reprogramming in mutant ESR1 cell models elicit diverse metastatic phenotypes related to cell adhesion and migration, which can be pharmacologically targeted in metastatic breast cancer.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Segunda Neoplasia Primária / Receptor alfa de Estrogênio / Células Neoplásicas Circulantes Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Segunda Neoplasia Primária / Receptor alfa de Estrogênio / Células Neoplásicas Circulantes Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article